Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$6.70 USD
+0.02 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.71 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
OBIO 6.70 +0.02(0.30%)
Will OBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OBIO
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Fortrea Holdings Inc. (FTRE) Q2 Earnings Expected to Decline
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?
Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know
Other News for OBIO
OBIO Crosses Above Key Moving Average Level
Orchestra BioMed initiated with bullish view at H.C. Wainwright, here's why
Orchestra BioMed reports Q2 results
Piper Sandler Remains a Buy on Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update